These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 31609457

  • 1. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
    Ranganath LR, Milan AM, Hughes AT, Khedr M, Davison AS, Shweihdi E, Norman BP, Hughes JH, Bygott H, Luangrath E, Fitzgerald R, Psarelli EE, van Kan C, Laan D, Olsson B, Rudebeck M, Mankowitz L, Sireau N, Arnoux JB, Le Quan Sang KH, Jarvis JC, Genovese F, Braconi D, Santucci A, Zatkova A, Glasova H, Stančík R, Imrich R, Rhodes NP, Gallagher JA.
    J Inherit Metab Dis; 2020 Jul; 43(4):737-747. PubMed ID: 31609457
    [Abstract] [Full Text] [Related]

  • 2. Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.
    Norman BP, Sutherland H, Wilson PJM, Rutland DA, Milan AM, Hughes AT, Davison AS, Khedr M, Jarvis JC, Gallagher JA, Bou-Gharios G, Ranganath LR.
    J Inherit Metab Dis; 2024 Jul; 47(4):664-673. PubMed ID: 38487984
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR, Khedr M, Milan AM, Davison AS, Hughes AT, Usher JL, Taylor S, Loftus N, Daroszewska A, West E, Jones A, Briggs M, Fisher M, McCormick M, Judd S, Vinjamuri S, Griffin R, Psarelli EE, Cox TF, Sireau N, Dillon JP, Devine JM, Hughes G, Harrold J, Barton GJ, Jarvis JC, Gallagher JA.
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [Abstract] [Full Text] [Related]

  • 5. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation.
    Introne WJ, Phornphutkul C, Bernardini I, McLaughlin K, Fitzpatrick D, Gahl WA.
    Mol Genet Metab; 2002 Sep; 77(1-2):136-42. PubMed ID: 12359141
    [Abstract] [Full Text] [Related]

  • 6. Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease-A review.
    Ranganath LR, Norman BP, Gallagher JA.
    J Inherit Metab Dis; 2019 Sep; 42(5):776-792. PubMed ID: 31282009
    [Abstract] [Full Text] [Related]

  • 7. Homogentisic acid induces autophagy alterations leading to chondroptosis in human chondrocytes: Implications in Alkaptonuria.
    Galderisi S, Milella MS, Rossi M, Cicaloni V, Rossi R, Giustarini D, Spiga O, Tinti L, Salvini L, Tinti C, Braconi D, Millucci L, Lupetti P, Prischi F, Bernardini G, Santucci A.
    Arch Biochem Biophys; 2022 Mar 15; 717():109137. PubMed ID: 35090868
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ, Keenan CM, Sutherland H, Wilson PJ, Wlodarski B, Taylor AM, Williams DP, Ranganath LR, Gallagher JA, Jarvis JC.
    Ann Rheum Dis; 2014 Jan 15; 73(1):284-9. PubMed ID: 23511227
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.
    Tinti L, Spreafico A, Chellini F, Galeazzi M, Santucci A.
    Clin Exp Rheumatol; 2011 Jan 15; 29(4):693-6. PubMed ID: 21813063
    [Abstract] [Full Text] [Related]

  • 15. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH, Wilson PJM, Sutherland H, Judd S, Hughes AT, Milan AM, Jarvis JC, Bou-Gharios G, Ranganath LR, Gallagher JA.
    J Inherit Metab Dis; 2020 Mar 15; 43(2):259-268. PubMed ID: 31503358
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria.
    Hughes JH, Liu K, Plagge A, Wilson PJM, Sutherland H, Norman BP, Hughes AT, Keenan CM, Milan AM, Sakai T, Ranganath LR, Gallagher JA, Bou-Gharios G.
    Hum Mol Genet; 2019 Dec 01; 28(23):3928-3939. PubMed ID: 31600782
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
    Tinti L, Spreafico A, Braconi D, Millucci L, Bernardini G, Chellini F, Cavallo G, Selvi E, Galeazzi M, Marcolongo R, Gallagher JA, Santucci A.
    J Cell Physiol; 2010 Oct 01; 225(1):84-91. PubMed ID: 20648626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.